Immix biopharma announces 75% complete response rate (n=16); 31.5 months best response duration (ongoing) for car-t nxc-201 in relapsed/refractory al amyloidosis patients at ash 2024

75% (12/16) complete response (cr) rate observed in standard of care (dara-cybord) relapsed/refractory al amyloidosis patients with median 4 lines of prior therapy in updated phase 1/2 data as of december 9, 2024 best responder duration of response was 31.5 months with complete response ongoing as of december 9, 2024 conference call to discuss results tuesday, december 10, 2024 4:30 p.m. et at https://zoom.us/j/94736340854?pwd=ltbtu2luvwsb6s6isuh5yktdlsi2vt.1 los angeles, ca, dec. 10, 2024 (globe newswire) -- immix biopharma, inc. (“immixbio”, “company”, “we” or “us” or ”immx”), a clinical-stage biopharmaceutical company developing cell therapies for al amyloidosis and select immune-mediated diseases, today announced that new nxc-201 nexicart-1 clinical data in relapsed/refractory al amyloidosis has been presented at 66th american society of hematology (ash) annual meeting being held in san diego, california.
CAR Ratings Summary
CAR Quant Ranking